Sunday, June 1, 2025
  • Login
Euro Times
No Result
View All Result
  • Home
  • Finance
  • Business
  • World
  • Politics
  • Markets
  • Stock Market
  • Cryptocurrency
  • Investing
  • Health
  • Technology
  • Home
  • Finance
  • Business
  • World
  • Politics
  • Markets
  • Stock Market
  • Cryptocurrency
  • Investing
  • Health
  • Technology
Euro Times
No Result
View All Result

European University to Fund Core One Labs’ Akome Advanced Neurogenesis Stimulation Studies

by Euro Times
October 15, 2022
in Markets
Reading Time: 4 mins read
A A
0
Home Markets
Share on FacebookShare on Twitter


VANCOUVER, BC / ACCESSWIRE / October 14, 2022 / Core One Labs Inc. (CSE:COOL)(OTCQB:CLABF)(Frankfurt:LD6)(WKN:A3CSSU) (the “Company” or “Core One“), further to its press release dated August 18, 2022, is excited to announce its wholly owned subsidiary, Akome Biotech Ltd. (“Akome“), the Company’s bio-pharma research and development division focused on new psychedelic-based drug discovery and development targeting neurological and mental health disorders, is finalizing discussions with Madrid’s Universidad Complutense (“Universidad Complutense”) to fund and initiate advancement of its neurogenesis stimulation studies (“neurogenesis studies“) relating to the effectiveness of its specific plant bioactives (“bioactive compounds) that comprise part of their patent pending psychedelic-based drug formulations. The Universidad Complutense has expressed a strong interest in advancing the next stage studies, and will providefunding to complete the studies, with Akome only required to provide raw materials.

As reported in the Company’s August 18, 2022, press release the neurogenesis studies, conducted by Universidad Complutense provide very encouraging results, having revealed that Akome’s selected bioactive compounds induce remarkable neurogenetic activity in controlled tests. Furthermore, the studies strongly suggest that each of Akome’s selected bioactive compounds have significant potential to elicit therapeutic activity against multiple neurologic conditions and could have therapeutic effects in more than just one targeted disease.

As a result of the encouraging studies results Akome, and Dr. Jose A. Morales-Garcia, Professor of Universidad Complutense and member of the Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED) from Carlos III Health Institute, have initiated discussions and are currently mapping out advanced neurogenesis models. The objectives of the next stage of the program include to test all Akome’s bioactive compounds in combination with select psychedelic compounds; to define potential pharmacodynamics; as well as to assist in the design of the next set of studies to demonstrate beneficial effects in animal models of the neurologic diseases and mental health conditions.

“The results of the initial study were very promising, and the Universidad Complutense is eager to move forward with the next stages of this trial and has offered to provide the funding required to conduct the research,” Core One CEO, Joel Shaker commented. “Moving forward with this advanced neurogenesis study in partnership with Universidad Complutense marks another significant step forward in the Company’s drug development pipeline.”

“The commitment expressed by Universidad Complutense to move forward with advanced neurogenesis studies, is a welcomed vote of confidence at this stage of our drug development process and marks another significant step forward and their potential for success.”

About Core One Labs Inc.

Core One Labs is a life sciences biotechnology research and development company focused on bringing psychedelic medicines to market through the development and production of psychedelic compounds, the advancement of psychedelic assisted treatments, and the integration of novel delivery systems technology.

The Company has a multi-faceted business approach and incorporates several complementary lines of businesses and units in establishing itself as an industry leader in the rapidly growing and emerging psychedelics market space.

Core One, through its wholly owned subsidiary Vocan Biotechnologies Inc., has developed and filed for patent protection of a proprietary psilocybin production system using engineered bacteria. It is also the holder of 4 provisional patents for the development of psychedelic-based pharmaceutical formulations targeting neurological and mental health disorders, under its 100% owned subsidiary Akome Biotech Ltd., and 3 provisional patents under its other 100% owned subsidiary, Awakened Biosciences Inc., for additional synthetic technologies for psilocybin and psilocin production methods.

In addition to the development of psychedelics and psychedelic compounds, Core One holds an interest in four medical clinics which maintain a combined database of more than 275,000 patients. Through its clinics the Company intends to integrate a roll out of its intellectual property related to psychedelic technologies and participate in the advancement of psychedelic-based treatments for mental health disorders.

Core One Labs Inc.

Joel Shacker
Chief Executive Officer

FOR MORE INFORMATION, PLEASE CONTACT:

[email protected]
1-866-347-5058

Cautionary Disclaimer Statement:

The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management’s current estimates, beliefs, intentions, and expectations. They are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, many of which are beyond the Company’s control. Such factors include, among other things: risks and uncertainties relating to the Company’s limited operating history and the need to comply with strict regulatory regulations. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.

In addition, psilocybin is currently a Schedule III drug under the Controlled Drugs and Substances Act (Canada) and it is a criminal offence to possess substances under the Controlled Drugs and Substances Act (Canada) without a prescription or authorization. Health Canada has not approved psilocybin as a drug for any indication. Core One does not have any direct or indirect involvement with illegal selling, production, or distribution of psychedelic substances in jurisdictions in which it operates. While Core One believes psychedelic substances can be used to treat certain medical conditions, it does not advocate for the legalization of psychedelics substances for recreational use. Core One does not deal with psychedelic substances, except within laboratory and clinical trial settings conducted within approved regulatory frameworks.

SOURCE: Core One Labs Inc.

View source version on accesswire.com:
https://www.accesswire.com/720546/European-University-to-Fund-Core-One-Labs-Akome-Advanced-Neurogenesis-Stimulation-Studies



Source link

Tags: AdvancedAkomeCoreEuropeanfundLabsNeurogenesisStimulationStudiesUniversity
Previous Post

Biden campaigns with Katie Porter on work to lower drug costs

Next Post

What to expect from China’s party congress

Related Posts

Why JPMorgan hired NOAA’s Sarah Kapnick as chief climate scientist

Why JPMorgan hired NOAA’s Sarah Kapnick as chief climate scientist

by Diana Olick
June 1, 2025
0

Sarah Kapnick began her profession in 2004 as an funding banking analyst for Goldman Sachs. She was struck nearly instantly...

Insurance stocks Lemonade, Mercury among biggest financial gainers of the week

Insurance stocks Lemonade, Mercury among biggest financial gainers of the week

by Liz Kiesche
May 31, 2025
0

Could 31, 2025 10:25 AM ETXLF, KB, MCY, MARA, TRUP, CLSK, BTC-USD, PLMR, LMND, GLXY, ETOR, AIFUBy: Liz Kiesche, SA...

Can Costco (COST) remain resilient against tariff headwinds this year?

Can Costco (COST) remain resilient against tariff headwinds this year?

by Staff Correspondent
May 31, 2025
0

Costco Wholesale Company (NASDAQ: COST) this week reported greater gross sales and revenue for the third quarter, regardless of tariff-related...

This is why Jamie Dimon is always so gloomy on the economy

This is why Jamie Dimon is always so gloomy on the economy

by Hugh Son
May 31, 2025
0

Jamie Dimon, CEO of JPMorgan Chase, testifies in the course of the Senate Banking, Housing and City Affairs Committee listening...

Did a Secret Court Just Halt Trump’s Tariffs?

Did a Secret Court Just Halt Trump’s Tariffs?

by Ian King
May 31, 2025
0

Final Friday, I walked out of the grocery retailer shaking my head. I had simply picked up a bottle of...

Earnings Summary: CooperCompanies (COO) reports higher Q2 revenue and profit

Earnings Summary: CooperCompanies (COO) reports higher Q2 revenue and profit

by Staff Correspondent
May 30, 2025
0

Medical system maker CooperCompanies (NYSE: COO) has reported a rise in adjusted earnings for the second quarter of 2025, aided...

Next Post
What to expect from China’s party congress

What to expect from China's party congress

Rupert Murdoch considers combining Fox, News Corp By Reuters

Rupert Murdoch considers combining Fox, News Corp By Reuters

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Cory Booker makes controversial ‘Nazi’ gesture at convention, Elon Musk reacts

Cory Booker makes controversial ‘Nazi’ gesture at convention, Elon Musk reacts

June 1, 2025
Ethereum Climbs In Key Channel After Triple Consolidation Setup

Ethereum Climbs In Key Channel After Triple Consolidation Setup

June 1, 2025
UK to dramatically increase weapons production — RT World News

UK to dramatically increase weapons production — RT World News

June 1, 2025
Dingdong Stock: Steady Growth Amid Margin Pressure, Waiting Better Entry Point (NYSE:DDL)

Dingdong Stock: Steady Growth Amid Margin Pressure, Waiting Better Entry Point (NYSE:DDL)

June 1, 2025
BAD OMEN? Lights Go Out in Bill Maher’s Studio When He Brings Up Joe Biden’s Mental Decline (VIDEO) | The Gateway Pundit

BAD OMEN? Lights Go Out in Bill Maher’s Studio When He Brings Up Joe Biden’s Mental Decline (VIDEO) | The Gateway Pundit

June 1, 2025
Ross Ulbricht Auctions Prison Memorabilia, ID Card Sells For 11 Bitcoin

Ross Ulbricht Auctions Prison Memorabilia, ID Card Sells For 11 Bitcoin

June 1, 2025
Euro Times

Get the latest news and follow the coverage of Business & Financial News, Stock Market Updates, Analysis, and more from the trusted sources.

CATEGORIES

  • Business
  • Cryptocurrency
  • Finance
  • Health
  • Investing
  • Markets
  • Politics
  • Stock Market
  • Technology
  • Uncategorized
  • World

LATEST UPDATES

Cory Booker makes controversial ‘Nazi’ gesture at convention, Elon Musk reacts

Ethereum Climbs In Key Channel After Triple Consolidation Setup

  • Disclaimer
  • Privacy Policy
  • DMCA
  • Cookie Privacy Policy
  • Terms and Conditions
  • Contact us

Copyright © 2022 - Euro Times.
Euro Times is not responsible for the content of external sites.

No Result
View All Result
  • Home
  • Finance
  • Business
  • World
  • Politics
  • Markets
  • Stock Market
  • Cryptocurrency
  • Investing
  • Health
  • Technology

Copyright © 2022 - Euro Times.
Euro Times is not responsible for the content of external sites.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In